Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood-Brain Barrier Permeability in Cases of Post-operative Delirium Is Associated with Central Nervous System Phosphatidylcholine Imbalances.

Molecular neurobiology·2026
Same author

Unraveling the role of polyamine metabolism in postoperative delirium: insights into biochemical mechanisms and biomarker potential.

npj aging·2026
Same author

Report of the 2024 Perioperative Cognition and Delirium Workshop.

British journal of anaesthesia·2025
Same author

Identifying subphenotypes of patients undergoing post-operative delirium assessment.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Duke activity status index is not predictive of outcomes after kidney transplantation: a retrospective observational study.

BMC nephrology·2025
Same author

Research on the perspectives of people affected by dementia with Lewy bodies: a scoping review.

Alzheimer's research & therapy·2025
Same journal

Digital twins in menopause: a roadmap for integrating endocrine dynamics, multisystem physiology, and precision medicine.

Maturitas·2026
Same journal

Testosterone therapy in women: Keeping pace with the evidence.

Maturitas·2026
Same journal

Diagnosis and management of androgen excess presenting after menopause.

Maturitas·2026
Same journal

Domain-specific severity of menopausal symptoms and emotional eating in midlife women.

Maturitas·2026
Same journal

Energy-based therapies for vulvar lichen sclerosus: A systematic review of randomized controlled trials.

Maturitas·2026
Same journal

Change of sexual activity and its relation to the quality of life in older people: Cognition of Older People, Education, Recreational Activities, NutritIon, Comorbidities, fUnctional Capacity Studies (COPERNICUS).

Maturitas·2026
See all related articles

Related Experiment Videos

Drug development in dementia.

Emma L Cunningham1, Anthony P Passmore

  • 1Centre for Public Health, Queen's University of Belfast, Block B, Institute of Clinical Sciences, Royal Victoria Hospital, Belfast BT12 6BA, United Kingdom.

Maturitas
|May 28, 2013
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) is the most common dementia cause. Developing disease-modifying drugs targeting amyloid processing and other pathways shows promise, but requires early detection through biomarkers due to the long preclinical phase.

Keywords:
APIAlzheimer's diseaseAlzheimer's prevention initiativeDIANDementiaDrugsN-methyl-d-aspartateNMDARNA binding proteinTDP-43Therapeutic developmentsdominantly inherited Alzheimer's network

Related Experiment Videos

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Dementia is a progressive cognitive decline impacting daily functioning, with Alzheimer's disease (AD) as the most prevalent cause.
  • Current drug development for AD is guided by evolving pathophysiological theories.
  • Therapeutic strategies aim to modify disease progression by targeting key pathways like amyloid processing, tau aggregation, neuroinflammation, and insulin signaling.

Purpose of the Study:

  • To review the current landscape of drug development for Alzheimer's disease.
  • To highlight the central role of the amyloid cascade in emerging AD therapies.
  • To emphasize the need for robust biomarkers for early detection and intervention.

Main Methods:

  • Review of current scientific literature on dementia and Alzheimer's disease.
  • Analysis of drug development strategies targeting specific pathophysiological pathways in AD.
  • Discussion of the importance of biomarkers in the context of AD progression.

Main Results:

  • Despite numerous efforts, disease-modifying treatments for AD have faced challenges, yet hold ongoing promise.
  • The amyloid cascade hypothesis remains a central focus for many novel therapeutic approaches.
  • The long preclinical phase of AD underscores the critical need for effective biomarkers.

Conclusions:

  • Drug development for Alzheimer's disease is complex, with multiple targets under investigation.
  • Early identification of individuals at risk via reliable biomarkers is essential for timely therapeutic intervention.
  • Continued research into disease-modifying therapies, particularly those addressing the amyloid cascade, is crucial for combating AD.